PURPOSE: To design a smart nano-vehicle (SNV) capable of permeating the blood-brain barrier (BBB) to target cerebrovascular amyloid formed in both Alzheimer's disease (AD) and cerebrovascular amyloid angiopathy (CAA). METHODS: SNV consists of a chitosan polymeric core prepared through ionic gelation with tripolyphosphate. A polyamine modified F(ab') portion of IgG4.1, an anti-amyloid antibody, was coated as a biosensor on the SNV surface. A similar polymeric core coated with bovine serum albumin (BSA) served as a control nano-vehicle (CNV). The BBB uptake of (125)I-SNVs and (125)I-CNVs was evaluated in mice. The uptake and transcytosis of SNVs and CNVs across bovine brain microvascular endothelial cells (BBMECs) was evaluated using flow cytometry and confocal microscopy. RESULTS: Plasma clearance of (125)I-SNVs was nine times higher than that of the (125)I-CNVs. However, the uptake of (125)I-SNVs in various brain regions was about 8 to 11 times higher than that of (125)I-CNVs. The uptake of FITC-BSA loaded SNVs in BBMECs was twice the uptake of FITC-BSA loaded CNVs. Confocal micrographs demonstrated the uptake and transcytosis of Alexa Fluor 647 labeled SNVs, but not CNVs, across the BBMEC monolayer. CONCLUSIONS: SNVs are capable of carrying a payload of model protein across the BBB to target cerebral amyloid.
PURPOSE: To design a smart nano-vehicle (SNV) capable of permeating the blood-brain barrier (BBB) to target cerebrovascular amyloid formed in both Alzheimer's disease (AD) and cerebrovascular amyloid angiopathy (CAA). METHODS:SNV consists of a chitosan polymeric core prepared through ionic gelation with tripolyphosphate. A polyamine modified F(ab') portion of IgG4.1, an anti-amyloid antibody, was coated as a biosensor on the SNV surface. A similar polymeric core coated with bovineserum albumin (BSA) served as a control nano-vehicle (CNV). The BBB uptake of (125)I-SNVs and (125)I-CNVs was evaluated in mice. The uptake and transcytosis of SNVs and CNVs across bovine brain microvascular endothelial cells (BBMECs) was evaluated using flow cytometry and confocal microscopy. RESULTS: Plasma clearance of (125)I-SNVs was nine times higher than that of the (125)I-CNVs. However, the uptake of (125)I-SNVs in various brain regions was about 8 to 11 times higher than that of (125)I-CNVs. The uptake of FITC-BSA loaded SNVs in BBMECs was twice the uptake of FITC-BSA loaded CNVs. Confocal micrographs demonstrated the uptake and transcytosis of Alexa Fluor 647 labeled SNVs, but not CNVs, across the BBMEC monolayer. CONCLUSIONS:SNVs are capable of carrying a payload of model protein across the BBB to target cerebral amyloid.
Authors: Joseph F Poduslo; Muthu Ramakrishnan; Silvina S Holasek; Marina Ramirez-Alvarado; Karunya K Kandimalla; Emily J Gilles; Geoffry L Curran; Thomas M Wengenack Journal: J Neurochem Date: 2007-07 Impact factor: 5.372
Authors: David J Mc Carthy; Meenakshi Malhotra; Aoife M O'Mahony; John F Cryan; Caitriona M O'Driscoll Journal: Pharm Res Date: 2014-12-02 Impact factor: 4.200
Authors: Kristen M Jaruszewski; Geoffry L Curran; Suresh K Swaminathan; Jens T Rosenberg; Samuel C Grant; Subramanian Ramakrishnan; Val J Lowe; Joseph F Poduslo; Karunya K Kandimalla Journal: Biomaterials Date: 2013-12-09 Impact factor: 12.479
Authors: Muthu Ramakrishnan; Karunya K Kandimalla; Thomas M Wengenack; Kyle G Howell; Joseph F Poduslo Journal: Biochemistry Date: 2009-11-03 Impact factor: 3.162
Authors: Chen Fang; Kui Wang; Zachary R Stephen; Qingxin Mu; Forrest M Kievit; Daniel T Chiu; Oliver W Press; Miqin Zhang Journal: ACS Appl Mater Interfaces Date: 2015-03-18 Impact factor: 9.229
Authors: Kristen M Jaruszewski; Subramanian Ramakrishnan; Joseph F Poduslo; Karunya K Kandimalla Journal: Nanomedicine Date: 2011-06-24 Impact factor: 5.307
Authors: M Malatesta; M Giagnacovo; M Costanzo; B Conti; I Genta; R Dorati; V Galimberti; M Biggiogera; C Zancanaro Journal: Eur J Histochem Date: 2012-04-16 Impact factor: 3.188